Company signals
LSEG (London Stock Exchange Group)
1 signal in the current window, with MitchelLake's leadership read on each.
Last updated
Market context: Against a Talent Market Index of 112.9 (Hot) (up 11.4 month-on-month), EMEA is at easing (-3.2pts) on signal share.
LSEG (London Stock Exchange Group): 1 signal in the last 90 days; 0.1% of MitchelLake's EMEA signal flow.
Signals at LSEG (London Stock Exchange Group)
In their words — LSEG (London Stock Exchange Group)
Verbatim from named people across LSEG (London Stock Exchange Group)'s signals — every line linked to its original source.
“It isn't traditional strategic M&A. It's more capital investment, with corporates, venture capital, and private equity funding these companies. It's driving a major level of dollar volume and will be the story of 2026.”
MitchelLake in this thematic
More signals across EMEA
Product Launch · EMEA
Siteimprove →Siteimprove launched a new MCP (Model Context Protocol) Server that integrates accessibility capabilities into AI workflows across Lovable, Anthropic Claude, VS Code, and Figma, enabling automated accessibility in digital experience creation.
Product Launch · EMEA
ST Engineering →ST Engineering secured a US$87.1 million UK defence contract to provide nine variants of 40mm high and low velocity grenades to the military.
Product Launch · EMEA
CSL →CSL's Tavenos product faced a regulatory setback in the European Union, flagged as a potential challenge to the biotechnology major
Product Launch · EMEA
JFrog →JFrog is gaining analyst momentum for AI-focused tools and software supply chain security offerings, with strong traction in managing AI development workflows and securing cloud-native software pipelines.
Product Launch · EMEA
Globant →Globant introduced AI Pods-powered Synthetic Operator for automated live-stream monitoring, targeting mission-critical media workflows with agentic AI tools.
Product Launch · EMEA
MSD →MSD's pembrolizumab received NICE recommendation for locally advanced cervical cancer (LACC), representing first immunotherapy approval in this indication in England
Intelligence powered by Autonodal ↗